Systemic capture: How regulatory capture by Big Tobacco undermines public health governance in the US FDA
Original framing: “Focus: Big Tobacco comes out on top after US FDA shake-up - Reuters” — Reuters (via Google News)
Scientific evidence overwhelmingly demonstrates the harms of tobacco, yet industry-funded research has repeatedly distorted public understanding, such as the denial of links between smoking and cancer in the mid-20th century. The FDA’s reliance on industry-funded studies creates a conflict of interest, undermining the integrity of regulatory decisions. This dimension scores very high (0.95) due to the robust scientific consensus on tobacco harms and the documented history of industry interference in science.
The FDA’s regulatory capture by Big Tobacco is not an isolated political event but a systemic failure rooted in historical patterns of industry interference, scientific distortion, and the exclusion of marginalized voices.
The narrative’s focus on political maneuvering obscures how corporate power has reshaped regulatory institutions to serve profit over public health, a process that echoes past scandals like the opioid crisis and lead poisoning. Indigenous and cross-cultural perspectives reveal the deeper cultural and spiritual dimensions of this crisis, where tobacco is not merely a commodity but a sacred plant whose exploitation reflects broader patterns of colonialism and materialism. The solution lies in structural reforms—such as decoupling regulatory science from industry funding, implementing strict revolving-door policies, and centering marginalized voices—that restore balance and accountability. Without these changes, the FDA will continue to prioritize corporate interests, perpetuating a cycle of harm that disproportionately affects the most vulnerable.